"Abstract
Objective: To examine key pharmaceutical product withdrawals and derive lessons that inform the current use of gene-based COVID-19 vaccines.
Results
COVID-19 gene-based vaccines: The key failure is to have mandated injections in young and healthy adults; these mandates correlate with excess mortality. A recent peer-reviewed study...finds over three million excess deaths from January 2020 to December 2022. Notably...the highest number of excess deaths was reported in 2021, the year in which mass vaccination began. Additional lessons potentially are that rushed 'warp speed' development of novel technologies is unwise; narrative and groupthink can distort judgement; suppression of clinical trial data is harmful; heightened active pharmacovigilance must be encouraged...
Discussion
Corporate integrity and data transparency: ...Internal industry documents...reveal a systemic pattern geared towards 'marketing-based medicine' that is at odds with 'evidence-based medicine.'
Among many examples, an internal AstraZeneca email discussed “burial” of data from four clinical trials...
Lack of recognition of pharmacovigilance data: ...A polio vaccine was withdrawn after just 10 death reports, the Swine Flu vaccine of 1976 was recalled after just 25 of the ultimate 53 death reports.
Not only are adverse events exceedingly high for the COVID-19 vaccines compared to all other vaccines...but deaths related to vaccines based per million doses show an unprecedented performance for the COVID-19 gene-based agents...
Pharmacovigilance underestimation factor: ...Vioxx data suggests the FDA’s adverse event database (FAERS) underestimates deaths by a factor of 5- to 9-fold... Yet, since the advent of the COVID-19 vaccines, health authorities have strenuously suggested the unprecedented adverse events are over-reported and thus overestimated...
In the US, government quality assurance suggests that the CDC’s VAERS under-reports by a factor of 10- to 100-fold – that only 1%–10% of all serious vaccine injuries are recorded. VAERS sensitivity to capture serious adverse events well-known to be caused by vaccines, namely anaphylaxis and Guillain-Barré syndrome, ranged from 12% to 76%, but mostly around 25% for several vaccines. In other words, an underestimation factor of 4-fold.
These pharmacovigilance databases err decidedly on the side of underestimation, not overestimation."
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).